{"schema_version":"secwatch.filing_event.v1","accession":"0001683168-25-000627","form_type":"8-K","ticker":"ACON","cik":"0001635077","company_name":"Aclarion, Inc.","filed_at":"2025-01-31T23:59:59+00:00","discovered_at":"2026-05-14T18:03:04.256493+00:00","generated_at":"2026-05-27T04:42:52.893243+00:00","sec_items":["1.01","7.01","9.01"],"event_type":"other_material","sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"confidence":"high","headline":"Aclarion prices $4.7M registered direct offering of 506,803 shares at $9.25 each","bullets":["Gross proceeds ~$4.7M; 506,803 shares at $9.25/share; closing expected Jan 31, 2025.","Net proceeds to fund market development, clinical evidence, product development, and G&A.","Dawson James Securities serving as sole placement agent; offering under effective S-3 shelf.","Offering priced at the market; no change to previously announced business plans."],"urls":{"canonical":"https://secwatch.observer/filing/0001683168-25-000627","json":"https://secwatch.observer/filing/0001683168-25-000627.json","markdown":"https://secwatch.observer/filing/0001683168-25-000627.md","text":"https://secwatch.observer/filing/0001683168-25-000627.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1635077/000168316825000627/0001683168-25-000627-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1635077/000168316825000627/acon_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-27T04:42:52.893243+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}